With great know-how, commercial excellence and investment in capabilites IDT Biologika achieved major successes, together with its customers and partners, in the development of cell lines for viral manufacturing, fighting the most serious diseases affecting people worldwide.
IDT Biologika is considered the global leader in MVA (Modified Vaccinia Ankara) and recombinant and non-recombinant poxvirus technologies and septic processing
Development and qualification of own seed cell banks for vaccine manufacturing. VERO and DF-1 (immortalized , non-tumorigenic chicken cell line): qualified for use in human products
Development of scalable upstream and downstream technologies for adherent cells with higher yield.
Major advantage for development of safe live viral vaccines using non- tumorigenic cell lines
Development and qualification of an immortalized duck cell line for suspension technologies for use in vaccines in collaboration with ProBiogen. Cell line (AGE-1) now successfully used for a range of clinical vaccines
CEPI Awards contract worth up to $36 mio to a consortium led by IDT Biologika to develop a Middle East Respiratory Syndrome (MERS) vaccine (2018)
Experiences in the development and manufacture of Ebola vaccines
Development of a scalable technology for manufacturing of small pox vaccines. Transferred to Bavarian Nordic and used for manufacturing of more than 20 mio doses of stockpiled smallpox vaccine (Elstree and MVA BN)
Thomas Jefferson University received a $30 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) to prepare and test a vaccine formulation that was designed to protect against the deadly Ebola, Sudan, Marburg, and Lassa fever viruses. Development of the manufacturing process and manufacture of the vaccine bei IDT Biologika. (2017)
